Oxford Biomedica issues new shares to secure a £17m investment MARKETS Cell and gene therapy company Oxford Biomedica has announced a near £17m investment which will see it issue new shares to the London Stock Exchange.
Astrazeneca swallows up Canada-based Fusion Pharmaceuticals in £1.5bn move Business Astrazeneca has completed its $2bn (£1.5bn) acquisition of Canada-based Fusion Pharmaceuticals, in a deal first announced in March.
‘New era of growth’: FTSE 100 giant Astrazeneca aims to double revenue pharma London-listed Astrazeneca reported revenue of $45.8bn in 2023 and growth of 19 per cent to $12.7bn in the first quarter of 2024.
Astrazeneca to build huge new cancer drug plant in Singapore May 20, 2024 Astrazeneca has said it will invest $1.5bn (£1.2bn) to build a manufacturing facility in Singapore to produce antibody drug conjugates (ADCs), a next-generation cancer treatment.
Astrazeneca: London-listed pharma giant heralds successful breast cancer drug April 29, 2024 Astrazeneca has found that Enhertu helped patients live longer without their breast cancer getting worse compared to standard chemotherapy.
How much is too much? The CEO pay predicament April 23, 2024 A growing number of London-listed companies have been asking shareholders to approve radical pay rises for their top execs. Why?
Global top 50 companies: UK absent as American tech triumphs April 22, 2024 There are now no UK companies among the top 50 largest listed companies in the world, as the British economy has struggled to compete with the dominance of American tech firms.
Flush FTSE 100 giant Astrazeneca to give more back to shareholders with dividend hike April 11, 2024 AstraZeneca will increase its annual dividend for the year by $0.20 (16p) to $3.10 (£2.47) per share
Are LVMH, Nestle, L’Oreal and Hermes Europe’s alternative to Microsoft, Apple, Nvidia and Tesla? April 9, 2024 Much has been made of the 'Magnificent Seven' tech stocks - Meta, Apple, Amazon. Alphabet, Microsoft, Nvidia and Tesla - which have dominated the US market amid a boom in demand for AI and, until recently, more optimism over potential interest rate cuts.
Covid-19 anniversary: How have GSK and Astrazeneca fared since? March 23, 2024 The Covid-19 pandemic also ignited interest in the pharmaceutical sector. Even before the UK went into lockdown, the sector was looking for ways to fight the virus.